<DOC>
	<DOCNO>NCT00324103</DOCNO>
	<brief_summary>In last year Structured Treatment Interruptions ( STI ) propose reduce HAART-related toxicity increase patient ’ compliance . ISS PART randomize comparison repeat STIs versus continuous HAART chronically HIV-infected subject persistent suppression viral replication . The two arm study compare term immunological response ( proportion patient CD4 &gt; 500/mmc ) 2 year .</brief_summary>
	<brief_title>Structured Treatment Interruptions Chronic HIV Infection</brief_title>
	<detailed_description>Patients randomize 1 1 ratio continue current antiretroviral regimen ( Arm A ) undergo structure treatment interruption ( STI ) ( Arm B ) accord follow scheme : STIs 1 , 1 , 2 , 2 3 month follow 3-month therapy period . During STIs , therapy resume presence HIV-RNA rebound &gt; 50,000 copies/ml CD4+ T cell decline &gt; 25 % baseline count ( &gt; 35 % patient CD4+ &gt; 500/mm3 randomization ) . After first cycle , subsequent STIs perform HIV-RNA level &lt; 400 copies/ml reach 2 month therapy resumption . At time treatment interruption patient arm B treatment non-nucleoside reverse transcriptase inhibitor suspend drug first continue treatment drug combination 3 day nevirapine-treated 6 day case previous efavirenz-based regimen . Patients see clinical site every three month arm A monthly arm B . On occasion , blood sample obtain biochemical viro-immunological assessment . The toxicity grade scale AIDS Clinical Trial Group ( ACTG ) use report clinical laboratory adverse event . In arm B , plasma genotype obtain sample take 15 30 day drug suspension . Patients discontinue study case : early therapy resumption 2 consecutive time ( arm B patient ) ; acute retroviral syndrome ( arm B patient ) ; AIDS-defining event ; severe adverse event ; pregnancy ; non-compliance ; patient ’ request ; physician ’ decision .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>firstline antiretroviral therapy ( 3 4 drug ) 6 18 month ( one previous therapy change toxicity noncompliance allow ) HIVRNA level 400 copies/ml least 6 month ; CD4+ count &gt; 350 /mm3 ; preHAART CD4+ &gt; 100/mm3 previous AIDS diagnosis . Previous antiretroviral therapy 1 2 drug ( except ARV prophylaxis pregnancy ) Pregnancy breastfeed Previous diagnosis AIDS Grade 3 4 adverse event 15 day enrolment Neoplasia Previous therapy IL2 , interferon ( last 2 year ) experimental therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>HIV</keyword>
	<keyword>Chronic Infection</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Structured Treatment Interruption</keyword>
</DOC>